CARDIFF ONCOLOGY INC NAMES MANI MOHINDRU PRESIDENT AND CEO; HE WILL REMAIN ON THE BOARD
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 09 2026
0mins
Should l Buy CRDF?
Source: moomoo
Leadership Announcement: Manihindru has been appointed as the President and CEO of Cardiff Oncology.
Board Membership: He will continue to serve as a member of the board.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRDF?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRDF
Wall Street analysts forecast CRDF stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.800
Low
10.00
Averages
13.67
High
19.00
Current: 1.800
Low
10.00
Averages
13.67
High
19.00
About CRDF
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cardiff Oncology Appoints New CEO and Executives
- Executive Appointments: Cardiff Oncology has appointed Mani Mohindru as President and CEO, who previously served as interim CEO and will remain on the Board, a move aimed at ensuring leadership stability and continuity within the company.
- Financial and Operational Leadership: Josh Muntner has been appointed CFO and Ajay Aggarwal as COO, effective April 6 and April 27 respectively, with Muntner having prior experience as CFO at Imvax and Mesoblast, while Aggarwal brings expertise from his role as Senior VP at Aclaris Therapeutics, enhancing the company's leadership depth.
- Strategic Execution Capability: The addition of these executives is expected to bolster Cardiff Oncology's capabilities in clinical development and financial management, particularly in advancing its treatment strategies for RAS-mutated metastatic colorectal cancer, potentially accelerating clinical strategy implementation.
- Market Reaction: Despite the leadership changes, the market remains cautious about Onvansertib's potential in first-line colorectal cancer treatment, reflecting investor concerns and expectations regarding the company's future trajectory.
See More
CARDIFF ONCOLOGY INC NAMES JOSH MUNTNER CFO STARTING APRIL 6 AND AJAY AGGARWAL COO BEGINNING APRIL 27
- New Appointments: Josh Munter and Jay Aggarwal have been appointed as Chief Financial Officers (CFOs) at Cardiff Oncology.
- Effective Dates: Josh Munter's appointment is effective from April 6, while Jay Aggarwal's is effective from April 27.
See More
CARDIFF ONCOLOGY INC NAMES MANI MOHINDRU PRESIDENT AND CEO; HE WILL REMAIN ON THE BOARD
Leadership Announcement: Manihindru has been appointed as the President and CEO of Cardiff Oncology.
Board Membership: He will continue to serve as a member of the board.
See More
Cardiff Oncology Reports 2025 Financial Results and Business Update
- Financial Overview: Cardiff Oncology reported royalty revenues of $0.6 million for 2025, a slight decrease from $0.7 million in 2024, while total operating expenses remained stable at $49.6 million, resulting in a net loss of $45.9 million or $0.69 per share, which is an improvement over the previous year's loss of $45.5 million or $0.95 per share, indicating better financial management.
- Clinical Trial Progress: The Phase 2 CRDF-004 trial for RAS-mutated metastatic colorectal cancer showed that the 30 mg Onvansertib combined with FOLFIRI/bev achieved a 72.2% objective response rate, significantly higher than the 43.2% in standard care arms, laying a solid foundation for advancing into a registrational program, with detailed data and regulatory plans expected in the first half of 2026.
- Cash Position: As of 2025, Cardiff's cash, cash equivalents, and short-term investments totaled $58.3 million, which is expected to fund operations into the first quarter of 2027, demonstrating strong financial management and providing a buffer for ongoing research and development.
- Leadership Changes: In January 2026, Cardiff announced executive changes with Mani Mohindru appointed as interim CEO and Brigitte Lindsay promoted to Chief Accounting Officer, reflecting the company's strategic restructuring to support late-stage development while actively searching for a permanent CEO and CFO to enhance management stability.
See More
Cardiff Oncology Reports FY EPS Beat Amid Revenue Decline
- Earnings Highlights: Cardiff Oncology reported a FY GAAP EPS of -$0.69, beating expectations by $0.08, indicating some financial resilience despite still being in negative territory.
- Revenue Trends: The company generated $0.59M in revenue, a 13.2% year-over-year decline, yet it surpassed market expectations by $0.14M, suggesting a stable customer base amid challenges.
- Leadership Changes: Following the earnings release, Cardiff Oncology experienced a leadership shakeup, which could impact the company's strategic direction and investor confidence, necessitating close monitoring of management stability.
- Future Outlook: Despite current challenges, the market remains cautiously optimistic about Cardiff Oncology's future performance, particularly with the upcoming Phase II data update for Onvansertib in RAS-mutated mCRC, which may present new growth opportunities.
See More
Cardiff Oncology Management Shakeup and Trial Update
- Management Changes: Cardiff Oncology announced the resignation of CEO Mark Erlander and CFO James Levine, with board member Mani Mohindru appointed as interim CEO, reflecting a focus on execution and clinical advancement that may impact investor confidence negatively.
- Clinical Trial Data Update: In the CRDF-004 Phase 2 trial for RAS-mutated metastatic colorectal cancer, the 30 mg dose group achieved a confirmed objective response rate of 72.2%, significantly higher than the 43.2% in the standard care group, indicating the potential efficacy of the new drug and possibly driving future registrational trials.
- Registrational Trial Plans: Based on clinical data, Cardiff Oncology plans to initiate a registrational trial later this year comparing onvansertib with standard care for 1L patients, which, if successful, could help expand market share.
- Analyst Perspective: William Blair lowered the probability of success from 50% to 45%, suggesting that the abrupt management changes and narrow focus on onvansertib may limit market opportunities, leading to a 31.9% drop in stock price to $2, close to the 52-week low.
See More
Cardiff Oncology Appoints New CEO and Executives
- Executive Appointments: Cardiff Oncology has appointed Mani Mohindru as President and CEO, who previously served as interim CEO and will remain on the Board, a move aimed at ensuring leadership stability and continuity within the company.
- Financial and Operational Leadership: Josh Muntner has been appointed CFO and Ajay Aggarwal as COO, effective April 6 and April 27 respectively, with Muntner having prior experience as CFO at Imvax and Mesoblast, while Aggarwal brings expertise from his role as Senior VP at Aclaris Therapeutics, enhancing the company's leadership depth.
- Strategic Execution Capability: The addition of these executives is expected to bolster Cardiff Oncology's capabilities in clinical development and financial management, particularly in advancing its treatment strategies for RAS-mutated metastatic colorectal cancer, potentially accelerating clinical strategy implementation.
- Market Reaction: Despite the leadership changes, the market remains cautious about Onvansertib's potential in first-line colorectal cancer treatment, reflecting investor concerns and expectations regarding the company's future trajectory.
See More
CARDIFF ONCOLOGY INC NAMES JOSH MUNTNER CFO STARTING APRIL 6 AND AJAY AGGARWAL COO BEGINNING APRIL 27
- New Appointments: Josh Munter and Jay Aggarwal have been appointed as Chief Financial Officers (CFOs) at Cardiff Oncology.
- Effective Dates: Josh Munter's appointment is effective from April 6, while Jay Aggarwal's is effective from April 27.
See More
CARDIFF ONCOLOGY INC NAMES MANI MOHINDRU PRESIDENT AND CEO; HE WILL REMAIN ON THE BOARD
Leadership Announcement: Manihindru has been appointed as the President and CEO of Cardiff Oncology.
Board Membership: He will continue to serve as a member of the board.
See More
Cardiff Oncology Reports 2025 Financial Results and Business Update
- Financial Overview: Cardiff Oncology reported royalty revenues of $0.6 million for 2025, a slight decrease from $0.7 million in 2024, while total operating expenses remained stable at $49.6 million, resulting in a net loss of $45.9 million or $0.69 per share, which is an improvement over the previous year's loss of $45.5 million or $0.95 per share, indicating better financial management.
- Clinical Trial Progress: The Phase 2 CRDF-004 trial for RAS-mutated metastatic colorectal cancer showed that the 30 mg Onvansertib combined with FOLFIRI/bev achieved a 72.2% objective response rate, significantly higher than the 43.2% in standard care arms, laying a solid foundation for advancing into a registrational program, with detailed data and regulatory plans expected in the first half of 2026.
- Cash Position: As of 2025, Cardiff's cash, cash equivalents, and short-term investments totaled $58.3 million, which is expected to fund operations into the first quarter of 2027, demonstrating strong financial management and providing a buffer for ongoing research and development.
- Leadership Changes: In January 2026, Cardiff announced executive changes with Mani Mohindru appointed as interim CEO and Brigitte Lindsay promoted to Chief Accounting Officer, reflecting the company's strategic restructuring to support late-stage development while actively searching for a permanent CEO and CFO to enhance management stability.
See More
Cardiff Oncology Reports FY EPS Beat Amid Revenue Decline
- Earnings Highlights: Cardiff Oncology reported a FY GAAP EPS of -$0.69, beating expectations by $0.08, indicating some financial resilience despite still being in negative territory.
- Revenue Trends: The company generated $0.59M in revenue, a 13.2% year-over-year decline, yet it surpassed market expectations by $0.14M, suggesting a stable customer base amid challenges.
- Leadership Changes: Following the earnings release, Cardiff Oncology experienced a leadership shakeup, which could impact the company's strategic direction and investor confidence, necessitating close monitoring of management stability.
- Future Outlook: Despite current challenges, the market remains cautiously optimistic about Cardiff Oncology's future performance, particularly with the upcoming Phase II data update for Onvansertib in RAS-mutated mCRC, which may present new growth opportunities.
See More
Cardiff Oncology Management Shakeup and Trial Update
- Management Changes: Cardiff Oncology announced the resignation of CEO Mark Erlander and CFO James Levine, with board member Mani Mohindru appointed as interim CEO, reflecting a focus on execution and clinical advancement that may impact investor confidence negatively.
- Clinical Trial Data Update: In the CRDF-004 Phase 2 trial for RAS-mutated metastatic colorectal cancer, the 30 mg dose group achieved a confirmed objective response rate of 72.2%, significantly higher than the 43.2% in the standard care group, indicating the potential efficacy of the new drug and possibly driving future registrational trials.
- Registrational Trial Plans: Based on clinical data, Cardiff Oncology plans to initiate a registrational trial later this year comparing onvansertib with standard care for 1L patients, which, if successful, could help expand market share.
- Analyst Perspective: William Blair lowered the probability of success from 50% to 45%, suggesting that the abrupt management changes and narrow focus on onvansertib may limit market opportunities, leading to a 31.9% drop in stock price to $2, close to the 52-week low.
See More
